Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer

Centre Georges Francois Leclerc3 enrolled

Overview

This study evaluates the dose received by the prostate with in vivo dosimetry when delivering image guided radiation therapy (IGRT) associated with intensity modulated radiation therapy (IMRT) for patients with localized prostate cancer using two repositioning techniques: fiduciary markers or soft tissues.

10 participants will receive a cone beam computed tomography (CBCT) repositioning, while the other 10 will receive a kV imaging of fiducial marker repositioning. The principal objective is to evaluate and compare the dose received by the prostate using two repositioning techniques.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

CBCTOTHER

10 participants will receive a cone beam computed tomography (CBCT) repositioning

fiducial marker (kV imaging)OTHER

10 participants will receive a kV imaging of fiducial marker repositioning.

IGRT Associated With IMRTRADIATION

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * male \> 18 years * carcinoma of the prostate histologically confirmed * OMS 0-1 * localized stage * favorable, intermediate and unfavorable groups according to NCCN or D'Amico classification * patients must have signed a written informed consent form * patients must be affiliated to a Social Health Insurance. Exclusion Criteria: * metastasis * indication for pelvic radiation * anticoagulant therapy * lateral or bilateral hip replacement * patient receiving an adult protective services * Patient unable to comply with the required medical follow-up for geographic, social or psychological reasons

Locations (1)

Centre Georges-François Leclerc

Dijon, France

Outcomes

Primary Outcomes

dosimetry (measurement of the absorbed dose, delivered to prostate, by ionizing radiation)

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.